Rhythm(US:RYTM)2023-08-01 18:35Commercial Performance & Market Access - IMCIVREE is now commercially available in Canada and GCC states, with a German BBS launch underway[1] - Strong U S demand for IMCIVREE for BBS continues[36] - Global net revenue for Q2 2023 reached $19 2 million, compared to $2 3 million in Q2 2022[116] - Approximately 86% of Q2 2023 revenue came from U S sales of IMCIVREE, up from 83% in Q1 2023[105] - Over 250 prescribers as of June 30, 2023, with over 25% of prescribers having written more than one prescription[77, 96] - Approximately 80% of Medicaid covered lives are in states with positive coverage policies or decisions for IMCIVREE[13] Clinical Development & Pipeline - Mean BMI reduction of 21 0% from baseline observed in 13 patients at six months[6] - IND application for RM-718 on track to be filed by the end of 2023[2] - Enrollment completion in Phase 3 hypothalamic obesity trial anticipated by the end of 2023[65, 87] Financial Position - Pro forma cash, cash equivalents, and short-term investments totaled $278 0 million as of June 30, 2023[105]